Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 14/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11834615 | 0.86 | MAT2A (0.64) | MAT2AFNTAFNTBBRD4RXFP1 | |
| SCHEMBL11825860 | 0.76 | MAT2A (0.48) | MAT2AFNTAFNTBBRD4PDE2A | |
| SCHEMBL11825891 | 0.74 | MAT2A (0.47) | MAT2AFNTAFNTBBRD4PDE2A | |
| SCHEMBL11822371 | 0.72 | MAT2A (0.46) | MAT2AFNTAFNTBBRD4 | |
| SCHEMBL11828073 | 0.71 | FNTA (0.46) | MAT2AFNTAFNTBBRD4PDE2A | |
| SCHEMBL23743012 | 0.70 | MAT2A (1.00) | MAT2AFNTAFNTB | |
| SCHEMBL30787877 | 0.68 | MAT2A (0.62) | MAT2AFNTAFNTBMAPTRXFP1 | |
| SCHEMBL1599263 | 0.65 | HPGD (0.41) | MAT2AFNTAFNTBBRD4 | |
| SCHEMBL11826249 | 0.65 | HSD11B1 (0.47) | MAT2AFNTAFNTBBRD4PDE2A | |
| SCHEMBL11823985 | 0.64 | SMN1; SMN2 (0.45) | BRD4PDE2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006032470-A1 | COMPOUNDS WHICH INCREASE APOLIPOPROTEIN A-1 PRODUCTION AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |